These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 27234763)

  • 1. Impact of mTOR Inhibitors on Cancer Development in Kidney Transplantation Recipients: A Population-Based Study.
    Kao CC; Liu JS; Lin MH; Hsu CY; Chang FC; Lin YC; Chen HH; Chen TW; Hsu CC; Wu MS
    Transplant Proc; 2016 Apr; 48(3):900-4. PubMed ID: 27234763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of mechanistic target of rapamycin inhibitors on postrenal transplantation malignancy: A nationwide cohort study.
    Hou YC; Chang YC; Luo HL; Lu KC; Chiang PH
    Cancer Med; 2018 Sep; 7(9):4296-4307. PubMed ID: 30117312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients.
    Opelz G; Unterrainer C; Süsal C; Döhler B
    Nephrol Dial Transplant; 2016 Aug; 31(8):1360-7. PubMed ID: 27190384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients.
    Badve SV; Pascoe EM; Burke M; Clayton PA; Campbell SB; Hawley CM; Lim WH; McDonald SP; Wong G; Johnson DW
    Clin J Am Soc Nephrol; 2016 Oct; 11(10):1845-1855. PubMed ID: 27445164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular risk in kidney transplant recipients receiving mammalian target of rapamycin inhibitors.
    Watorek E; Szymczak M; Boratynska M; Patrzalek D; Klinger M
    Transplant Proc; 2011 Oct; 43(8):2967-9. PubMed ID: 21996202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Incidence of Ovarian Cysts in Women Receiving mTOR Inhibitors After Renal Transplantation.
    Bachmann F; Glander P; Budde K; Bachmann C
    J Womens Health (Larchmt); 2018 Mar; 27(3):394-398. PubMed ID: 29087803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mTOR inhibitor monotherapy. A good treatment choice in renal transplantation?
    Franco-Esteve A; Tordera D; de la Sen ML; Jiménez L; Mas P; Muñoz C; Olivares J
    Nefrologia; 2012; 32(5):631-8. PubMed ID: 23013949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion to mammalian target of rapamycin inhibitors in kidney transplant recipients with de novo cancers.
    Cheung CY; Man Ma MK; Chak WL; Chau KF; Tang SCW
    Oncotarget; 2017 Jul; 8(27):44833-44841. PubMed ID: 28160552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical insights for cancer outcomes in renal transplant patients.
    Alberú J
    Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex difference for urologic malignancy risk in uremic patients after kidney transplantation: a population-based study.
    Hwang JC; Jiang MY; Lu YH; Weng SF
    Transplantation; 2015 Apr; 99(4):818-22. PubMed ID: 25208323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins in Kidney Transplant Recipients: Usage, All-Cause Mortality, and Interactions with Maintenance Immunosuppressive Agents.
    Bae S; Ahn JB; Joseph C; Whisler R; Schnitzler MA; Lentine KL; Kadosh BS; Segev DL; McAdams-DeMarco MA
    J Am Soc Nephrol; 2023 Jun; 34(6):1069-1077. PubMed ID: 36890643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion to mTOR-inhibitors with calcineurin inhibitor elimination or minimization reduces urinary polyomavirus BK load in kidney transplant recipients.
    Yen CL; Tian YC; Wu HH; Weng CH; Chen YC; Tu KH; Liu SH; Lee CC; Lai PC; Fang JT; Hung CC; Yang CW; Li YJ
    J Formos Med Assoc; 2016 Jul; 115(7):539-46. PubMed ID: 26994751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+/R-) kidney transplant recipients.
    Cristelli MP; Esmeraldo RM; Pinto CM; Sandes-Freitas TV; Felipe C; Lobo CF; Viana L; Mansur J; Stopa S; Santos DWC; Grenzi PC; Aguiar WF; Tedesco-Silva H; Pestana JOM
    Transpl Infect Dis; 2018 Aug; 20(4):e12907. PubMed ID: 29679515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
    Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
    Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
    Valantine H
    J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal.
    Doesch AO; Müller S; Konstandin M; Celik S; Kristen A; Frankenstein L; Ehlermann P; Sack FU; Katus HA; Dengler TJ
    Transplant Proc; 2010 Nov; 42(9):3694-9. PubMed ID: 21094840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.
    Sánchez-Escuredo A; Diekmann F; Revuelta I; Esforzado N; Ricart MJ; Cofán F; Torregrosa JV; Peri L; Ruiz Á; Campistol JM; Oppenheimer F
    Transpl Int; 2016 Mar; 29(3):362-8. PubMed ID: 26678359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with everolimus is associated with a procoagulant state.
    Baas MC; Gerdes VE; Ten Berge IJ; Heutinck KM; Florquin S; Meijers JC; Bemelman FJ
    Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid.
    Radtke J; Dietze N; Spetzler VN; Fischer L; Achilles EG; Li J; Scheidat S; Thaiss F; Nashan B; Koch M
    Transpl Infect Dis; 2016 Feb; 18(1):79-88. PubMed ID: 26707694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of mTOR-Is on malignancy and survival following renal transplantation: A systematic review and meta-analysis of randomized trials with a minimum follow-up of 24 months.
    Wolf S; Hoffmann VS; Habicht A; Kauke T; Bucher J; Schoenberg M; Werner J; Guba M; Andrassy J
    PLoS One; 2018; 13(4):e0194975. PubMed ID: 29659588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.